31 articles tagged with #bernstein. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Circle (CRCL) stock has surged 49% year-to-date in 2026, with investment firm Bernstein setting a bullish $190 price target. The positive outlook is driven by USDC stablecoin growth, expanding payments adoption, and emerging AI finance opportunities.
Bernstein analysts predict 70% upside potential for Circle as stablecoin adoption grows in payments and AI applications. Circle shares surged nearly 10% to $111.84 on Monday, reaching their highest level since early November.
Circle shares reached $90 as analysts from Bernstein highlighted the company's divergence from pure crypto exposure, while Mizuho noted a boost from Polymarket integration. The company is generating incremental higher-margin revenue through infrastructure expansion beyond traditional reserve income.
Bernstein forecasts a potential 212% surge in Coinbase stock despite the exchange reporting $667 million in losses for Q4 2025, representing a 151% increase from Q4 2024. The analyst firm suggests investors should 'take the pain here rather than panic' amid current challenges.
Bernstein has reaffirmed an outperform rating on AstraZeneca (AZN), identifying its non-oncology portfolio as significantly undervalued with 37% upside potential to a £186 price target. The stock gained 3.1% on the analyst note, suggesting market recognition of hidden value in overlooked business segments.
Figure reported a 156% jump in Q4 profit, prompting Bernstein analysts to maintain their outperform rating and $72 price target. The analysts described the quarterly results as 'solid' and expressed increased confidence in the company.
